Summary
Quest Diagnostics Incorporated, a leader in diagnostic information services, reported $7.5 billion in net revenues for 2015. The company's strategy, initiated in 2012, focuses on restoring growth, driving operational excellence, simplifying the organization, refocusing on core diagnostic information services, and disciplined capital deployment. Significant progress has been made in restoring growth through initiatives like sales and marketing excellence and expanding esoteric testing. Operational improvements are being driven by the 'Invigorate' cost excellence program, which aims for substantial savings. The company is also actively pursuing strategic partnerships and acquisitions to enhance its market position and service offerings.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $7.49B |
| Cost of Revenue | $4.66B |
| Gross Profit | $2.84B |
| SG&A Expenses | $1.68B |
| Operating Expenses | $6.09B |
| Operating Income | $1.40B |
| Interest Expense | $154.00M |
| Net Income | $709.00M |
| EPS (Basic) | $4.92 |
| EPS (Diluted) | $4.87 |
| Shares Outstanding (Basic) | 144.00M |
| Shares Outstanding (Diluted) | 145.00M |
Key Highlights
- 1Quest Diagnostics generated $7.5 billion in net revenues for the year ended December 31, 2015.
- 2The company's strategy centers on five key pillars: restoring growth, driving operational excellence, simplifying the organization, refocusing on diagnostic information services, and disciplined capital deployment.
- 3Restoring growth is being pursued through near-term opportunities such as sales and marketing excellence and growing esoteric testing, and longer-term initiatives like precision medicine and international expansion.
- 4Operational excellence is being driven by the 'Invigorate' cost excellence program, which has achieved over $700 million in run-rate savings by year-end 2014 and continues to deliver savings.
- 5The company has divested non-core assets and contributed its central laboratory testing for clinical trials business to a joint venture (Q2 Solutions) to sharpen its focus on core diagnostic information services.
- 6Quest Diagnostics is committed to disciplined capital deployment, returning a majority of free cash flow to investors through dividends and share repurchases, with 80% of free cash flow returned in 2015.
- 7The company emphasizes innovation, introducing over 20 new or enhanced disease area solutions in 2015, particularly in areas like oncology, cardiovascular health, and infectious diseases.
Frequently Asked Questions
Quest Diagnostics is the world's leading provider of diagnostic information services. They offer a broad range of clinical testing services, including routine, gene-based, esoteric, and anatomic pathology testing, along with related services and insights. They serve a significant portion of the U.S. adult population annually and are a major player in providing diagnostic information to clinicians, hospitals, health plans, and employers.
Quest Diagnostics is actively working to restore growth through strategies like enhancing sales and marketing, expanding esoteric testing with a disease-specific focus, and pursuing strategic partnerships with hospitals and IDNs. They are also investing in innovation, introducing new tests and services, particularly in areas like precision medicine, oncology, and infectious diseases, to address evolving healthcare needs.
The company is driving operational excellence through its 'Invigorate' cost excellence program, which aims to achieve substantial run-rate savings by improving efficiency across the value chain, including revenue services, IT, procurement, and laboratory operations. They are also investing in automation and technology platforms to enhance customer experience and reduce labor costs.
Quest Diagnostics follows a disciplined capital deployment framework focused on increasing shareholder returns and return on invested capital (ROIC). This includes returning a majority of free cash flow to investors through dividends and share repurchases. In 2015, they returned 80% of their free cash flow to investors and announced an increase in their quarterly dividend. They also selectively pursue strategically aligned accretive acquisitions.